Hemolytic jaundice induced by pharmacological dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency

A case report

Shuxie Wu, PhD\textsuperscript{a}, Gao Wu, MD\textsuperscript{b}, Hanbin Wu, MD\textsuperscript{c}.\textsuperscript{*}

Abstract

Rationale: Hemolysis induced by high dose ascorbic acid (AA) in patients with G6PD deficiency has been reported, but is rare. To our knowledge, this is the first reported case of a male with G6PD deficiency, coexpressed with cholecystolithiasis and cholecystitis, who developed extreme hemolysis and hyperbilirubinemia after receiving pharmacological doses ascorbic acid infusion.

Patient concerns: A 27-year-old man history with glucose-6-phosphate dehydrogenase deficiency was admitted to our hospital because of cholecystolithiasis and cholecystitis. He appeared with scleral jaundice and very deep colored urine after receiving pharmacological doses ascorbic acid infusion.

Diagnoses: Clinical findings when combined with his medical history and various laboratory results confirmed the diagnosis as hemolysis and hyperbilirubinemia induced by ascorbic acid.

Interventions: The patient was treated with steroids, hepatoprotective drugs, and folic acid in addition avoidance of agents with known hemolysis risk (such as vitamin C).

Outcomes: As a result, the patient’s symptoms from hemolytic jaundice improved, hemoglobin remained stable, and the patient was discharged 11 days later.

Lessons: Clinicians should bear in mind the possibility that vitamin C exposure may result in hemolysis in patients with G6PD deficiency, especially in those with known severe disease.

Abbreviations: AA = ascorbic acid, aPTT = activated partial thromboplastin time, CAM = Complementary and Alternative Medicine, DHEA = dehydroepiandrosterone, Fer = ferritin, G6PD = glucose-6-phosphate dehydrogenase, Glut = glucose transporter, GSH = reduced glutathione, GSSG = oxidized glutathione, Hb = hemoglobin, NADPH = nicotinamide adenine dinucleotide phosphate, PPP = pentosephosphate pathway, PT = prothrombin time, RBC = red blood cell count, ROS = reactive oxygen species, SVCT = sodium-dependent ascorbic acid transporter, US = ultrasonography, WBCC = white blood cell.

Keywords: ascorbic acid, dehydroascorbic acid, glucose-6-phosphate dehydrogenase (G6PD), hemolysis

1. Introduction

Glucose-6-phosphate dehydrogenase (G6PD) is the first and key enzyme of the pentosephosphate pathway (PPP), expressed in all tissues of the body.\textsuperscript{11} It is the enzyme that generates reduced nicotinamide adenine dinucleotide phosphate (NADPH), which enables cells to counterbalance the oxidative stress.\textsuperscript{12} G6PD deficiency is the most common enzymopathy in humans, affecting over 400 million people worldwide, and is an important cause of hemolytic anemia and neonatal jaundice.\textsuperscript{1,3} Hemolysis in G6PD deficient patients occurs after exposure to oxidant drugs, fava beans, infections, or severe acidosis.\textsuperscript{12,4,5} Hemolysis induced by high dose ascorbic acid (AA) in patients with G6PD deficiency has been reported, but is uncommon.\textsuperscript{6–8} We report here the first case of a male with G6PD deficiency, coexpressed with cholecystolithiasis and cholecystitis, who developed extreme hemolysis and hyperbilirubinemia after receiving pharmacological doses ascorbic acid infusion.

2. Case report

A 27-year-old man history with glucose-6-phosphate dehydrogenase deficiency presented to the emergency department complaining of one day of worsening right upper quadrant pain and distension but denied any nausea, vomiting, or fevers with negative Murphy’s sign, and there was no scleral icterus. Vital signs: Temperature 36.4°C, blood pressure 120/79 mm Hg, heart rate 68/min and respiratory rate 18/min. Ultrasonography (US) suggested cholecystolithiasis and cholecystitis. The patient was admitted to the hepatobiliary surgery. The patient received fasting treatment, anti-infective therapy, and nutrition, fluid
supplementation. On the first night of admission, antibiotics were started. Cefmetazole Sodium (Harbin Pharmaceutical Group Factory, Harbin, Heilongjiang, China) administered intravenously, 2g 2 times a day. Laboratory results upon admission to the initial hospital were notable for the following: red blood cell (RBC) count 3.12 × 10^{12}/L (4.3–5.8), hemoglobin (Hb) 114.0 g/L (130–175), white blood cell (WBC) count 6.04 × 10^{9}/L (3.5–9.5), absolute monocyte count 11.4% (3.0–10.0), platelet count 432.0 × 10^{12}/L (125–350), prothrombin time (PT) 14.1 seconds (9.8–12.1), activated partial thromboplastin time (aPTT) 30.7 seconds (25.0–31.3), ferritin (Fe) 3056.00 (30–400) ng/mL. On the second day, the patient received 5% compound amino acid injection (18) (Guangdong Liti Pharmaceutical Co., Ltd, PuNing, Guangdong, China) 250mL and alanyl glutamine 10g (Hainan Lionco Pharmaceutical Group Co., Ltd, Hai Kou, Hainan, China) IV once a day, and vitamin C 4g, vitamin B6 400mg and KCl 1g in 5% glucose and sodium chloride solution 250mL

3. Discussion

Glucose-6-phosphate dehydrogenase deficiency, an X-linked inherited genetic defect, is the most common human deficiency disease. G6PD catalyzes the rate-limiting step in the reduction of nicotinamide adenine dinucleotide phosphate (NADP) to NADPH. In addition, glucose-6-phosphate (G6P) can be shuttled into the PPP to produce NADP to NADPH by 6-phosphogluconate dehydrogenase (6PGD). NADPH, which is the major reducing equivalent produced by PPP to reduce NADP to NADPH by 6-phosphogluconate dehydrogenase (6PGD). NADPH is produced continuously as Hb cycles between its deoxygenated and oxygenated forms. This defense against oxidative stress or oxidizing agents in the blood as well as the oxygen radicals continuously generated as Hb cycles between its deoxygenated and oxygenated forms. This defense against oxidative stress or oxidizing agents is largely mediated through the glutathione cycle, whereby a steady regeneration of GSH depends on a steady supply of NADPH, and was highly dependent on the activity of G6PD enzyme.[14] In most cases, in the steady state, the consequences of G6PD deficiency are not noticeable. The NADPH produced by the residual G6PD activity and by 6PGD activity is just enough to keep the erythrocyte going, with marginal reduction of its life span. If an exogenous oxidative stress is applied, however, G6PD-deficient erythrocytes are unable to step up NADPH production, the reduced production of NADPH is not sufficient to neutralize the oxidative stress. As a consequence, GSH is rapidly depleted, Hb and other proteins are damaged, and eventually the erythrocyte becomes prey to macrophages or hemolyzes altogether.[15] Therefore, G6PD deficiency renders the erythrocytes more susceptible to oxidative damage than any other cells and eventual death.[16,17] Vitamin C (ascorbic acid, AA), which is an essential substance in humans because humans are unable to synthesize the vitamin, acts as a cofactor for 15 mammalian enzymes and as an electron donor and/or free radical scavenger to detoxify free radicals in body tissues. Vitamin C serves as a very important and powerful water-soluble antioxidant with the reduced form, AA, donating 2 electrons to oxidized form, dehydroascorbic acid (DHA).[17,18] Only reductive vitamin C, AA, has physiological and pharmacological effects. It is well known that vitamin C is a very important and powerful antioxidant drug that works in the aqueous environments of the body and protects cells against oxidation. Independent of its use to treat the deficiency disease scurvy, vitamin C has been used by Complementary and Alternative Medicine (CAM) practitioners to treat diverse conditions including infections, autoimmune diseases, cancer, and illnesses of uncertain origin.[19] Vitamin C is commonly called an antioxidant, but this terminology is misleading. Vitamin C also exhibits pro-oxidant activities. Electron from AA can reduce metals such as copper and iron, leading to the formation of superoxide and hydrogen peroxide, and subsequent generation of reactive oxidant species. Thus, under some circumstances vitamin C will generate oxidants.[18]
The RBCs also have rapid and efficient ascorbate recycling mechanisms for reducing DHA to AA by GSH to maintain adequate tissue levels of vitamin C. They must have potent oxidative properties by increasing accumulation of AA to protect against oxidative stress. The content of AA in cell can exceed by several orders of magnitude of the plasma levels. The reductive vitamin C is transported in a concentrative manner by sodium-dependent ascorbic acid transporter (SVCT) 1 and 2, and the oxidized form DHA transported by Gluts. The present study demonstrates that only vitamin C-defective mammals maintain Glut I expression on RBCs. As soon as DHA is transported, it undergoes immediate intracellular reduction to AA. The process of extracellular AA oxidation to DHA, transported as DHA, intracellular reduction to AA is termed ascorbate recycling.

However, human erythrocyte (RBC) is deficient in SVCT2, and express very high levels of Glut1. Erythrocytes take up significant amounts of DHA via their Glut1 glucose transporter and regenerate the protective, reduced form of AA to sustain high levels in erythrocytes. In certain pathological conditions, such as oxidative stress, DHA is likely to be generated in significant amounts in both plasma and cells in areas of inflammation or infection. Local DHA concentrations may be higher when cells produce reactive oxygen species, such as that by activated neutrophils and monocytes. In addition, when ascorbate is given pharmacologically, it is possible that DHA concentrations rise proportionately, since erythrocytes have a high capacity antioxidant systems to recycle AA from DHA, they can help to maintain the AA concentration in plasma. The high DHA uptake by circulating erythrocytes would then allow the AA redox molecule to be efficiently transported throughout the body. However, the main system for reducing DHA is at the expense of reducing endogenous GSH. In normal RBCs, DHA reduction stimulates the activity of glucose-6-phosphate dehydrogenase by facilitating the utilization of glucose through PPP, increases the supply of NADPH and maintains high level of GSH. Therefore, the use of DHA increases RBC antioxidant stores. However, in G6PD-deficient RBCs the production of NADPH is not sufficient, GSH is rapidly depleted in ascorbate recycling. Therefore, the uptake large amounts of DHA might produce an oxidative burden to RBCs, and intracellular DHA can act as an antioxidant for G6PD-deficient RBCs because of the formation of reactive oxygen species as a result of the interaction of DHA with iron.

In fact, DHA has been proposed as an indication of oxidative stress. It is not certain whether low level of RBC count and Hb at admission were caused by hemolysis induced by oxidative stress of infection as he has no colored urine and other evidence. A day after vitamin C 4g was administered, the patient developed scleral jaundice and very deeply colored urine. A peripheral blood tests showed a hemolytic jaundice. Other potential drugs of acute hemolysis, such as cefmetazole sodium, compound amino acid injection, alanine glutamine, vitamin B6, were unlikely in our patient on the basis of laboratory data and these chemical compositions, pharmacological activities, and there is no evidence in the literature implicating the drugs as a cause of hemolysis in individuals with G6PD deficiency. Zhang and colleagues showed that erythrocytes from a G6PD patient showed increased oxidative stress in response to AA and H2O2 treatments and the erythrocytes were also significantly more susceptible to VC-induced hemolysis. Their further experiments show that a PPP inhibitor, dehydroepiandrosterone (DHEA), significantly exacerbated VC-induced RBC hemolysis under all conditions. The intracellular conversion of DHA to AA is known to require glutathione, which may further facilitate ROS accumulation by reducing the cellular antioxidant defenses and increase intracellular oxidative radicals over a tolerable threshold in G6PD deficient RBC. Therefore, it is plausible that the vitamin C, acting in combination with an underlying oxidative trigger of infection, precipitated his acute hemolysis. The infection of cholecystitis and vitamin C act on erythrocytes together, and both contribute to increasing the oxidative stress of erythrocytes. Erythrocytes cannot increase its antioxidant capacity as G6PD deficiency and are subjected to oxidative damage and hemolysis. In our patient, the infection-related oxidative stress saturates the antioxidant capacity of erythrocytes, the administered intravenously pharmacologic dose of vitamin C is the last straw that breaks the Camel’s back.

In summary, we report a 27-year-old G6PD deficient man who presented with hemolytic jaundice found to cholecystolithiasis and cholecystitis. No clear trigger for his presentation was identified after an exhaustive workup but given the growing body of evidence which supports the role and mechanism of pharmacologic dose of ascorbic acid as a direct cause of hemolysis in this case. This case highlights the risk associated with ascorbic acid, especially in those with known severe disease, and the need for increased screening, before starting use to avoid hemolysis in high-risk individuals with G6PD deficiency. Clinicians should bear in mind the possibility that vitamin C exposure may result in hemolysis in patients with G6PD deficiency. As with our case, patients typically present with multiple comorbidities, which are risk for hemolysis, such as infections, and polypharmacy, which requires a thorough drug review for physicians to identify less widely known drugs that are usually considered safe, such as ascorbic acid, to ensure patient safety. Although ascorbic acid has been listed as the drugs to be used with caution in therapeutic doses for patients with G6PD deficiency in the package insert, it is difficult to correlate the contribution of ascorbic acid and the disease state with hemolysis. The key aspects to appropriate management are prompt recognition and avoidance of drugs with the potential to cause this adverse event.

4. Ethics approval and consent to participate

Not applicable. In the China, no ethical approval is required for anonymized studies with medical charts and patient data that were collected and noted for standard care.
5. Informed consent

Informed written consent was obtained from the patient for publication of this case report.

Author contributions

Investigation: Gao Wu, Hanbin Wu.
Writing – original draft: Shuxie Wu.
Writing – review & editing: Hanbin Wu.

Hanbin Wu: 0000-0002-2933-1570.

References

[1] Manganelli G, Fico A, Martini G, et al. Discussion on pharmacogenetic interaction in G6PD deficiency and methods to identify potential hemolytic drugs. Cardiovasc Hematol Disord Drug Targets 2010;10:143–50.
[2] Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am 2016;30:373–93.
[3] Tang J, Jiang C, Xiao X, et al. Changes in red blood cell membrane structure in G6PD deficiency: an atomic force microscopy study. Clin Chim Acta 2013;446:264–70.
[4] Manganelli G, Masullo U, Passarelli S, et al. Glucose-6-phosphate dehydrogenase deficiency: disadvantages and possible benefits. Cardiovasc Hematol Disord Drug Targets 2013;13:73–82.
[5] Bubp J, Jen M, Matuszewski K. Caring for glucose-6-phosphate dehydrogenase (G6PD)-deficient patients: implications for pharmacy. P T 2015;40:572–4.
[6] Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 1993;306:841–2.
[7] Huang YC, Chang TK, Fu YC, et al. C for colored urine: acute hemolysis induced by high-dose ascorbic acid. Clin Toxicol (Phila) 2014;52:984.
[8] Mehta JR, Singhal SB, Mehta BC. Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 1990;336:944.
[9] Maha AA. Effect of glucose-6-phosphate dehydrogenase deficiency on some biophysical properties of human erythrocytes. Hematology 2009;14:38–45.
[10] Cappellini MD, Fioretti G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64–74.
[11] Nóbrega-Pereira S, Fernandez-Marcos PJ, Brioche T, et al. G6PD protects from oxidative damage and improves healthspan in mice. Nat Commun 2016;7:10894.
[12] Yang HC, Wu YH, Liu HY, et al. What has passed is prolog: new cellular and physiological roles of G6PD. Free Radic Res 2016;50:1047–64.
[13] van Zwieten R, Verhoeven AJ, Roos D. Inborn defects in the antioxidant band 3 modiﬁcation. Transfus Med Hemother 2012;39:328–34.
[14] Al-EW, Ahmed EE. The role of erythrocyte enzyme glucose-6-phosphate dehydrogenase (G6PD) deﬁciency in the pathogenesis of anemia in patients on hemodialysis. Saudi J Kidney Dis Transpl 2013;24:1153–6.
[15] Pullar JM, Bayer S, Carr AC. Appropriate handling, processing and analysis of blood samples is essential to avoid oxidation of vitamin C to dehydroascorbic acid. Antioxidants (Basel) 2018;7:E29.
[16] Padayatty SJ, Levine M. Vitamin C: the known and the unknown and Goldilocks. Oral Dis 2016;22:463–93.
[17] Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010;5:e11414.
[18] Nuaalart FJ, Rivas CI, Montecinos V, et al. Recycling of Vitamin C by a bystander effect. J Biol Chem 2003;278:10128–33.
[19] Montel-Hagen A, Blanc L, Boyer-Clavel M, et al. The Glut1 and Glut4 glucose transporters are differentially expressed during perinatal and postnatal erythropoiesis. Blood 2008;112:4729–38.
[20] Montel-Hagen A, Kinet S, Manei N, et al. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 2008;132:1039–48.
[21] May JM, Qu ZC, Cobb CE. Human erythrocyte recycling of ascorbic acid: relative contributions from the ascorbate free radical and dehydroascorbic acid. J Biol Chem 2004;279:14975–82.
[22] Haque R, Carrathers A. Human erythrocytes transport dehydroascorbic acid and sugars using the same transporter complex. Am J Physiol Cell Physiol 2014;306:C910–7.
[23] Tian W, Wang Y, Xu Y, et al. The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C- induced toxicity. J Biol Chem 2014;289:3339–51.
[24] Shan F, Yang R, Ji T, et al. Vitamin C inhibits aggravated eryptosis by hydrogen peroxide in glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem 2016;39:1453–62.
[25] Tu H, Wang Y, Li H, et al. Chemical transport knockout for oxidized vitamin C, dehydroascorbic acid, reveals its functions in vivo. EBioMedicine 2017;23:125–35.
[26] Cisternas P, Silva-Alvarez C, Martinez F, et al. The oxidized form of vitamin C, dehydroascorbic acid, regulates neuronal energy metabolism. J Neurochem 2014;129:663–71.
[27] Tu H, Li H, Wang Y, et al. Low red blood cell vitamin C concentrations induce red blood cell fragility: a link to diabetes via glucose, glucose transporters, and dehydroascorbic acid. ElBioMedicine 2015;2:1735–50.
[28] Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010;5:e11414.
[29] Cisternas P, Silva-Alvarez C, Martinez F, et al. The oxidized form of vitamin C, dehydroascorbic acid, regulates neuronal energy metabolism. J Neurochem 2014;129:663–71.
[30] Theil EC. Ferritin: the protein nanocage and iron biomineral in health and in disease. Inorg Chem 2013;52:12223–33.
[31] Almeida SG, Veiga JP, Arruda SF, et al. The association of markers of oxidative stress and ferritin concentration: implications for pharmacy. P T 2015;40:572–4.
[32] Maha AA. Effect of glucose-6-phosphate dehydrogenase deficiency on some biophysical properties of human erythrocytes. Hematology 2009;14:38–45.
[33] Cappellini MD, Fioretti G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64–74.
[34] Nóbrega-Pereira S, Fernandez-Marcos PJ, Brioche T, et al. G6PD protects from oxidative damage and improves healthspan in mice. Nat Commun 2016;7:10894.
[35] van Zwieten R, Verhoeven AJ, Roos D. Inborn defects in the antioxidant band 3 modiﬁcation. Transfus Med Hemother 2012;39:328–34.
[36] Al-EW, Ahmed EE. The role of erythrocyte enzyme glucose-6-phosphate dehydrogenase (G6PD) deﬁciency in the pathogenesis of anemia in patients on hemodialysis. Saudi J Kidney Dis Transpl 2013;24:1153–6.
[37] Pullar JM, Bayer S, Carr AC. Appropriate handling, processing and analysis of blood samples is essential to avoid oxidation of vitamin C to dehydroascorbic acid. Antioxidants (Basel) 2018;7:E29.
[38] Padayatty SJ, Levine M. Vitamin C: the known and the unknown and Goldilocks. Oral Dis 2016;22:463–93.
[39] Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010;5:e11414.
[40] Nuaalart FJ, Rivas CI, Montecinos V, et al. Recycling of Vitamin C by a bystander effect. J Biol Chem 2003;278:10128–33.
[41] Montel-Hagen A, Blanc L, Boyer-Clavel M, et al. The Glut1 and Glut4 glucose transporters are differentially expressed during perinatal and postnatal erythropoiesis. Blood 2008;112:4729–38.
[42] Montel-Hagen A, Kinet S, Manei N, et al. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 2008;132:1039–48.
[43] May JM, Qu ZC, Cobb CE. Human erythrocyte recycling of ascorbic acid: relative contributions from the ascorbate free radical and dehydroascorbic acid. J Biol Chem 2004;279:14975–82.
[44] Sage JM, Carrathers A. Human erythrocytes transport dehydroascorbic acid and sugars using the same transporter complex. Am J Physiol Cell Physiol 2014;306:C910–7.
[45] Tian W, Wang Y, Xu Y, et al. The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C- induced toxicity. J Biol Chem 2014;289:3339–51.
[46] Shan F, Yang R, Ji T, et al. Vitamin C inhibits aggravated eryptosis by hydrogen peroxide in glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem 2016;39:1453–62.
[47] Tu H, Wang Y, Li H, et al. Chemical transport knockout for oxidized vitamin C, dehydroascorbic acid, reveals its functions in vivo. EBioMedicine 2017;23:125–35.